S&P 500 ends higher after Trump attacks Fed

The S&P 500 ended higher, primarily driven by gains in Nvidia ahead of its pivotal earnings report, which is set to influence AI stock valuations, and Eli Lilly, following positive trial data for its experimental weight-loss drug. Despite concerns over Federal Reserve independence stemming from President Trump's removal of a governor, market participants largely maintained expectations for a September interest rate cut. This occurred as the S&P 500 trades at a four-year high of 23 times expected earnings, making Nvidia's upcoming results particularly critical for broader market sentiment.

Analysis

The S&P 500 advanced 0.41%, approaching its record high, though the rally occurred on light trading volume, with 15.7 billion shares traded compared to the 20-day average of 16.9 billion. Gains were largely driven by a few key stocks, notably Eli Lilly, which jumped almost 6% after its experimental pill demonstrated a 10.5% body weight reduction in patients, and Nvidia, which rose 1.1% ahead of a highly anticipated earnings report. The market largely absorbed concerns over Federal Reserve independence following the politically motivated removal of a governor, as investor expectations for a September interest rate cut remain firm, a view now echoed by Morgan Stanley. This sentiment persists despite the S&P 500 trading at a four-year high valuation of 23 times expected earnings, heightening the market's sensitivity to Nvidia's results as a bellwether for the AI-driven rally. Other notable corporate actions included EchoStar's 70% surge on a $23 billion spectrum sale to AT&T and a 2% gain in Advanced Micro Devices following an upgrade to "buy" from Truist Securities. Despite the positive index performance, market breadth was narrow, with advancing issues outnumbering decliners by a slim 1.1-to-one ratio, indicating the gains were not broad-based.

Key Decisions for Investors

• Given the market's elevated valuation at 23 times forward earnings, investors should treat Nvidia's upcoming report as a critical risk event, as any disappointment could trigger a significant repricing in AI-related equities and the broader market.
• Consider positions in companies with strong idiosyncratic catalysts, such as Eli Lilly's positive drug trial results or EchoStar's value-unlocking M&A, as these events are driving significant outperformance in a market with narrow leadership.
• While the market currently anticipates a September rate cut, monitor upcoming inflation and employment data closely, as any deviation from expectations could challenge the dovish monetary policy narrative that is underpinning current asset prices.
• Note the light trading volume accompanying the market's rise, which suggests a potential lack of broad conviction and could signal vulnerability to a reversal should negative catalysts emerge.